10:35 AM EDT, 07/31/2025 (MT Newswires) -- Silexion Therapeutics ( SLXN ) shares surged 91% in recent Thursday trading after the company reported new preclinical data showing its RNA interference candidate SIL204 inhibited pancreatic cancer cell growth by up to 97% and colorectal cancer cells by nearly 90%.
The findings from a Cell Titer-Glo analysis showcased the drug's potency across several cancer types and Kirsten rat sarcoma viral oncogene homolog mutations.
Silexion plans to begin a phase 2/3 trial in Q2 2026 to evaluate SIL204 for the treatment of KRAS-driven solid tumor cancers, the company said.